Intelligence / Healthtech / New Clinical Trials / PT Bio Farma
Clinicaltrial registered10 Nov 2026
PT Bio Farma
10 Nov 2026: Trial registered · Cy-Tb for Detecting Mycobacterium Tuberculosis Infection in Indonesian Population. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 10 Nov 2026
- Title
- Cy-Tb for Detecting Mycobacterium Tuberculosis Infection in Indonesian Population
- Conditions
- TB Infection
- Phase
- Not applicable
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- Indonesia
- Country
- Indonesia
- Reference
- NCT07929285
- Location
- Indonesia
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at PT Bio Farma
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from Indonesia
New Clinical Trials
17 NovPT Equilab Internationaltrial registered · Nutritional Status Evaluation in Underweight Indonesian Children Receiving 0.89 kcal/mL Milk Powder - Site ManadoClinical17 NovPT Equilab Internationaltrial registered · Nutritional Status Evaluation in Underweight Indonesian Children Receiving 0.89 kcal/mL Milk Powder - Site MakassarClinical16 NovDexa Medica Grouptrial registered · The Efficacy and Safety of DLBS1442 in Patients With Primary DysmenorrheaClinical16 NovDexa Medica Grouptrial registered · Bioequivalence Study of Sitagliptin/Metformin 50 mg/1000 mg Extended Release TabletClinical16 NovDexa Medica Grouptrial registered · The Efficacy and Safety of DLBS3233 in Adults With PrediabetesClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.